Trevi Therapeutics, Inc. (TRVI) Nonoperating Income (Expense) USD 2018 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Trevi Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from 2018 to 2024.
  • Trevi Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending March 31, 2024 was $996 K, a 13.8% decline year-over-year.
  • Trevi Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending March 31, 2024 was $4.67 M, a 114% increase year-over-year.
  • Trevi Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $4.83 M, a 571% increase from 2022.
  • Trevi Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was $719 K.
  • Trevi Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was -$1.49 M, a 417% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $4.67 M $996 K -$159 K -13.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $4.83 M $1.13 M -$2 K -0.18% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-20
Q3 2023 $4.83 M $1.33 M +$1.2 M +911% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $3.63 M $1.21 M +$1.44 M Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-10
Q1 2023 $2.18 M $1.16 M +$1.46 M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $719 K $1.13 M +$1.39 M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-20
Q3 2022 -$666 K $132 K +$438 K Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$1.1 M -$236 K +$393 K +62.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$1.5 M -$309 K -$12 K -4.04% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$1.49 M -$253 K +$60 K +19.2% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-16
Q3 2021 -$1.55 M -$306 K -$161 K -111% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$1.38 M -$629 K -$643 K -4593% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$741 K -$297 K -$454 K -289% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$287 K -$313 K -$538 K -239% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-17
Q3 2020 $251 K -$145 K -$425 K -152% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $676 K $14 K -$52 K -78.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $728 K $157 K +$151 K +2517% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 $577 K $225 K +$327 K Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 $250 K $280 K +$1 M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$752 K $66 K +$569 K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$1.32 M $6 K +$940 K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$2.26 M -$102 K Oct 1, 2018 Dec 31, 2018 10-K 2020-03-16
Q3 2018 -$722 K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$503 K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-12
Q1 2018 -$934 K Jan 1, 2018 Mar 31, 2018 10-Q 2019-06-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.